AQR Capital Management LLC Increases Stake in Elanco Animal Health Incorporated $ELAN

Key Points

• AQR Capital Management LLC increased its holdings in Elanco Animal Health by 116.4%, acquiring a total of 524,507 shares valued at approximately $5.3 million.
• Elanco Animal Health reported a strong quarterly performance with $1.24 billion in revenue, surpassing expectations and showing a 4.8% year-over-year growth.
• Several brokerages have recently upgraded their ratings on Elanco, with a consensus rating of "Moderate Buy" and an average target price of $17.33 per share.

AQR Capital Management LLC lifted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 116.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 524,507 shares of the company's stock after acquiring an additional 282,081 shares during the quarter. AQR Capital Management LLC owned 0.11% of Elanco Animal Health worth $5,332,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Nuveen LLC bought a new stake in Elanco Animal Health during the 1st quarter valued at $115,212,000. Dimensional Fund Advisors LP raised its holdings in Elanco Animal Health by 14.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock valued at $214,875,000 after buying an additional 2,563,740 shares during the last quarter. ASR Vermogensbeheer N.V. bought a new stake in Elanco Animal Health during the 1st quarter valued at $23,744,000. DDD Partners LLC raised its holdings in Elanco Animal Health by 202.7% during the 1st quarter. DDD Partners LLC now owns 1,492,992 shares of the company's stock valued at $15,676,000 after buying an additional 999,716 shares during the last quarter. Finally, Shapiro Capital Management LLC raised its holdings in Elanco Animal Health by 7.5% during the 4th quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company's stock valued at $149,640,000 after buying an additional 862,900 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on ELAN shares. Stifel Nicolaus upped their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Zacks Research lowered shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Piper Sandler upped their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, August 11th. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Finally, Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of "Moderate Buy" and a consensus price target of $17.33.

Elanco Animal Health Stock Up 3.7%

Shares of NYSE:ELAN traded up $0.69 during midday trading on Thursday, reaching $19.12. The company's stock had a trading volume of 6,941,773 shares, compared to its average volume of 10,027,642. The firm has a 50 day moving average of $16.68 and a 200-day moving average of $13.39. The firm has a market capitalization of $9.50 billion, a P/E ratio of 22.23, a PEG ratio of 3.42 and a beta of 1.62. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $19.27.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company's revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.